CY1116487T1 - Παραγοντες συνδεσης αμυλοειδους - Google Patents

Παραγοντες συνδεσης αμυλοειδους

Info

Publication number
CY1116487T1
CY1116487T1 CY20151100606T CY151100606T CY1116487T1 CY 1116487 T1 CY1116487 T1 CY 1116487T1 CY 20151100606 T CY20151100606 T CY 20151100606T CY 151100606 T CY151100606 T CY 151100606T CY 1116487 T1 CY1116487 T1 CY 1116487T1
Authority
CY
Cyprus
Prior art keywords
amyloid
connection factors
factors
connection
disease
Prior art date
Application number
CY20151100606T
Other languages
English (en)
Inventor
Jerry Yang
Emmanuel A Theodorakis
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of CY1116487T1 publication Critical patent/CY1116487T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Παρέχονται ενώσεις και μέθοδοι για την ανίχνευση των αμυλοειδών και θεραπεία ασθενειών που σχετίζονται προς αμυλοειδή συμπεριλαμβανομένης ασθένειας Alzheimer και άλλων σχετικών βασιζόμενων σε αμυλοειδές νευροεκφυλιστικών ασθενειών.
CY20151100606T 2009-12-10 2015-07-13 Παραγοντες συνδεσης αμυλοειδους CY1116487T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28547009P 2009-12-10 2009-12-10
EP10836776.4A EP2509940B1 (en) 2009-12-10 2010-12-10 Amyloid binding agents

Publications (1)

Publication Number Publication Date
CY1116487T1 true CY1116487T1 (el) 2017-03-15

Family

ID=44146211

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100606T CY1116487T1 (el) 2009-12-10 2015-07-13 Παραγοντες συνδεσης αμυλοειδους

Country Status (26)

Country Link
US (3) US8940918B2 (el)
EP (1) EP2509940B1 (el)
JP (1) JP5591946B2 (el)
KR (3) KR20180041767A (el)
CN (2) CN103201258B (el)
AU (1) AU2010327918B2 (el)
BR (1) BR112012013810B1 (el)
CA (1) CA2783466C (el)
CY (1) CY1116487T1 (el)
DK (1) DK2509940T3 (el)
ES (1) ES2546063T3 (el)
HK (2) HK1177930A1 (el)
HR (1) HRP20150854T1 (el)
HU (1) HUE027199T2 (el)
IN (1) IN2012DN05186A (el)
ME (1) ME02194B (el)
MX (1) MX347591B (el)
NZ (1) NZ600459A (el)
PL (1) PL2509940T3 (el)
PT (1) PT2509940E (el)
RS (1) RS54158B1 (el)
RU (1) RU2517174C2 (el)
SG (1) SG181561A1 (el)
SI (1) SI2509940T1 (el)
SM (1) SMT201500216B (el)
WO (1) WO2011072257A2 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013180815A1 (en) * 2012-05-30 2013-12-05 University Of Tennessee Research Foundation Compounds for amide-forming reactions
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
TW201609183A (zh) 2013-10-31 2016-03-16 康諾普堤克斯公司 眼用調配物之製備方法及其用途
NZ719998A (en) * 2013-11-12 2017-08-25 Cognoptix Inc Method for measuring fluorescence in ocular tissue
AU2015231239B2 (en) 2014-03-19 2018-11-29 Amydis, Inc. Amyloid targeting agents and methods of using the same
EP3191107A2 (en) * 2014-09-12 2017-07-19 Amydis Diagnostics, Inc. In vitro compositions comprising human sample and amyloid targeting agent
WO2018208709A1 (en) 2017-05-09 2018-11-15 Warner Babcock Institute For Green Chemistry, Llc Stilbene derivatives for the treatment of cns and other disorders
JP7381500B2 (ja) * 2018-05-31 2023-11-15 アミディス， インコーポレイテッド 外傷性脳損傷を検出するための組成物および方法
WO2020093008A1 (en) * 2018-11-02 2020-05-07 Sarraf Stella Phosphate compounds for detecting neurological disorders
AU2022234434A1 (en) * 2021-03-12 2023-09-14 Amydis, Inc. Methods of detecting systemic amyloidosis via binding to misfolded or aggregated protein
CN115322165A (zh) * 2022-09-30 2022-11-11 镇江百单医疗生物科技有限公司 近红外荧光探针成像肝纤维化中亚铁离子的动态波动

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583614A (en) 1950-05-13 1952-01-29 Eastman Kodak Co Acylated methine dye compounds
US2798090A (en) * 1953-03-02 1957-07-02 Eastman Kodak Co Process for preparing benzalaniline-3-sulfonic acid compounds
US3074971A (en) * 1959-01-23 1963-01-22 Gen Aniline & Film Corp alpha-cyanocinnamic acid esters
US3149146A (en) * 1960-03-09 1964-09-15 Gen Aniline & Film Corp Alpha-cyano-2-alkenoxy-1-naphthaleneacrylic acid esters
FR1321641A (fr) * 1962-03-08 1963-03-22 Gen Aniline & Film Corp Nouvelles compositions absorbantes de rayons ultraviolets
BE794010A (fr) * 1972-01-13 1973-05-02 Du Pont Colorants cationiques de couleur jaune-vert
DE2714653C3 (de) * 1977-04-01 1980-10-30 Bayer Ag, 5090 Leverkusen Kationische Styrylfarbstoffe und Verfahren zum Färben mit diesen Farbstoffen
DE2942185A1 (de) * 1979-10-18 1981-04-30 Basf Ag, 6700 Ludwigshafen Basische farbstoffe
JPS5815912A (ja) * 1981-07-22 1983-01-29 Ss Pharmaceut Co Ltd 消炎鎮痛剤
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS63163826A (ja) * 1986-12-26 1988-07-07 Idemitsu Kosan Co Ltd 有機非線型光学材料
DE3905916A1 (de) * 1989-02-25 1990-08-30 Basf Ag Verwendung von derivaten des n-phenyl-3,4,5,6-tetrahydrophthalimids zur desikkation und abszission von pflanzenorganen
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE4430691A1 (de) * 1994-08-30 1996-03-07 Bayer Ag Elektrolumineszierende Anordnungen und deren Verwendung
WO2003062190A1 (en) * 2002-01-18 2003-07-31 The Hospital For Sick Children Compounds for modulating cell proliferation
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
WO2004078144A2 (en) * 2003-03-05 2004-09-16 Celgene Corporation Diphenylethylene compounds and uses thereof
WO2005073697A1 (en) * 2004-01-20 2005-08-11 The Curators Of The University Of Missouri Local flow and shear stress sensor based on molecular rotors
WO2005092904A1 (en) * 2004-03-26 2005-10-06 Hsc Research And Development Limited Partnership Novel compounds for modulating cell proliferation
AU2005310979A1 (en) * 2004-11-16 2006-06-08 Bellus Health (International) Limited Compounds for the treatment of CNS and amyloid associated diseases
WO2007011834A2 (en) 2005-07-15 2007-01-25 The Regents Of The University Of California Compounds and method for the diagnosis and treatment of amyloid associated diseases
US8895791B2 (en) 2006-07-31 2014-11-25 Basf Se Method of regenerating ruthenium catalysts suitable for hydrogenation
FR2905009A1 (fr) * 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
CN101209976B (zh) * 2006-12-29 2012-01-11 中国人民解放军军事医学科学院毒物药物研究所 取代的酒石酸衍生物及其用于制备β-分泌酶抑制剂的用途
WO2009052837A2 (en) * 2007-10-24 2009-04-30 Tallinn University Of Technology Maldi ms-based high-throughput screening method for substances inhibiting aggregation of alzheimer's amyloid beta peptides

Also Published As

Publication number Publication date
BR112012013810A2 (pt) 2020-08-25
BR112012013810B1 (pt) 2022-01-11
MX2012006552A (es) 2012-08-23
US20170315137A1 (en) 2017-11-02
EP2509940B1 (en) 2015-06-10
SMT201500216B (it) 2015-10-30
HK1177930A1 (en) 2013-08-30
CN105669597A (zh) 2016-06-15
MX347591B (es) 2017-05-03
KR102079160B1 (ko) 2020-02-19
IN2012DN05186A (el) 2015-10-23
RU2012128798A (ru) 2014-01-20
WO2011072257A2 (en) 2011-06-16
PT2509940E (pt) 2015-09-24
US20150177262A1 (en) 2015-06-25
NZ600459A (en) 2014-01-31
CA2783466C (en) 2019-09-24
EP2509940A2 (en) 2012-10-17
SI2509940T1 (sl) 2015-09-30
ES2546063T3 (es) 2015-09-18
CA2783466A1 (en) 2011-06-16
DK2509940T3 (en) 2015-07-20
PL2509940T3 (pl) 2015-11-30
ME02194B (me) 2016-02-20
CN105669597B (zh) 2019-05-07
KR20190109594A (ko) 2019-09-25
US20120302603A1 (en) 2012-11-29
US8940918B2 (en) 2015-01-27
US9551722B2 (en) 2017-01-24
CN103201258A (zh) 2013-07-10
HRP20150854T1 (hr) 2015-09-25
EP2509940A4 (en) 2013-04-17
AU2010327918B2 (en) 2014-01-16
AU2010327918A1 (en) 2012-06-21
HK1225729A1 (zh) 2017-09-15
JP2013513619A (ja) 2013-04-22
KR101849680B1 (ko) 2018-04-17
WO2011072257A3 (en) 2011-10-20
CN103201258B (zh) 2016-01-27
KR20120104306A (ko) 2012-09-20
RS54158B1 (en) 2015-12-31
JP5591946B2 (ja) 2014-09-17
KR20180041767A (ko) 2018-04-24
RU2517174C2 (ru) 2014-05-27
HUE027199T2 (en) 2016-08-29
SG181561A1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
CY1116487T1 (el) Παραγοντες συνδεσης αμυλοειδους
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1123746T1 (el) Ανθρωποποιημενα tau αντισωματα σε νοσο του alzheimer
CY2023004I2 (el) Συνθεσεις irna τρανσθυρετινης (ttr) και μεθοδοι χρησεως αυτων για τη θεραπευτικη αγωγη ή προληψη σχετιζομενων me ttr ασθενειων
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1119166T1 (el) Θεραπευτικες συνθεσεις νουκλεασης και μεθοδοι
CY1120172T1 (el) Αναστολεις κινασων σερινης/θρεονινης
CY1118187T1 (el) Χημικες ενωσεις
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
CY1116552T1 (el) Ανοσοθεραπευτικα σχηματα εξαρτωμενα απο την κατασταση αροε
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
CO6390078A2 (es) Inihibidores de syk de imidazopirazina
BRPI1006115A2 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
ATE557022T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
CY1115316T1 (el) Πεπτιδια για τη θεραπευτικη αγωγη βητα-αμυλοειδωσεων
ATE538652T1 (de) Synergistische pharmazeutische kombination für die behandlung von krebs
CO6910184A2 (es) Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide
CY1117582T1 (el) Χρηση μιμοτοπων των α-συνουκλεϊνης επιτοπων για θεραπεια ασθενειων σωματος lewy
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
CY1118968T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
EP2182978A4 (en) TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
EP3475707A4 (en) BLOOD TEST FOR THE EXCLUSION OF AMYLOID AND ALZHEIMER DISEASE
CY1117251T1 (el) Μεθοδοι θεραπευτικης αντιμετωπισης της σκληροδερμιας
WO2010000089A8 (en) Stat3 and tyk2 as drug targets for neurodegenerative diseases